Ionis Pharmaceuticals IONS Accrued Progress Collections and Price Adjustments
Accrued Progress Collections and Price Adjustments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's accrued progress collections and price adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's accrued progress collections and price adjustments?
- Ionis Pharmaceuticals (IONS) reported accrued progress collections and price adjustments of $75.75M in Q1 2026.
- How has Ionis Pharmaceuticals's accrued progress collections and price adjustments changed year-over-year?
- Ionis Pharmaceuticals's accrued progress collections and price adjustments decreased by 46.2% year-over-year, from $140.68M to $75.75M.
- What is the long-term trend for Ionis Pharmaceuticals's accrued progress collections and price adjustments?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's accrued progress collections and price adjustments has grown at a -26.3% compound annual growth rate (CAGR), from $424.05M to $92M.